Panacea Biotec shares hit 5% upper circuit on ₹127 crore contract from UNICEF; stock jumps 150% in 1 year

UNICEF will make each award public by publishing the following information on the UNICEF website:

• The supplier’s name, vaccine(s), duration of award, and total award value.

• awarded prices per supplier per product presentation per year.

Panacea Biotec shares have given impressive returns in the past 12 months. The stock price has zoomed 153.55% so far in 2024.

The net profit of Panacea Biotec came in at ₹4.71 crore for the quarter ended September 2024 (Q2 FY25) as against the net loss of ₹8.29 crore during the previous quarter ended September 2023.

Sales rose 3.03% to ₹147.35 crore during the quarter as against ₹143.02 crore logged during the previous quarter ended September 2023.

Panacea Biotec Ltd’s net profit margin jumped 154.7% from last year's same period to 3.04% in Q2 2024-2025. On a quarterly growth basis, Panacea Biotec Ltd has generated a 123.43% jump in its net profit margins in the last three months.